Daniel Almquist

439 total citations
18 papers, 303 citations indexed

About

Daniel Almquist is a scholar working on Oncology, Epidemiology and Molecular Biology. According to data from OpenAlex, Daniel Almquist has authored 18 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Epidemiology and 6 papers in Molecular Biology. Recurrent topics in Daniel Almquist's work include Neuroendocrine Tumor Research Advances (10 papers), Lung Cancer Research Studies (9 papers) and Neuroblastoma Research and Treatments (4 papers). Daniel Almquist is often cited by papers focused on Neuroendocrine Tumor Research Advances (10 papers), Lung Cancer Research Studies (9 papers) and Neuroblastoma Research and Treatments (4 papers). Daniel Almquist collaborates with scholars based in United States, Pakistan and Israel. Daniel Almquist's co-authors include Tanios Bekaii‐Saab, Daniel H. Ahn, Mohamad Bassam Sonbol, Vinicius Ernani, Jason S. Starr, Mitesh J. Borad, Kabir Mody, Pedro Luiz Serrano Usón, Wen Wee and Apar Kishor Ganti and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Daniel Almquist

18 papers receiving 302 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Almquist United States 8 169 103 102 85 59 18 303
Burcin Özdirik Germany 12 112 0.7× 154 1.5× 105 1.0× 55 0.6× 56 0.9× 24 319
Mark Karwal United States 9 147 0.9× 114 1.1× 123 1.2× 53 0.6× 61 1.0× 26 330
Denise N. Gansen United States 7 67 0.4× 72 0.7× 138 1.4× 66 0.8× 37 0.6× 8 272
Zhong-Guo Zhou China 11 196 1.2× 75 0.7× 147 1.4× 77 0.9× 62 1.1× 17 387
Loretta D’Onofrio Italy 8 137 0.8× 46 0.4× 93 0.9× 80 0.9× 60 1.0× 18 299
Ryu Otao Japan 10 122 0.7× 150 1.5× 236 2.3× 52 0.6× 45 0.8× 16 378
Satoshi Moriya Japan 11 85 0.5× 141 1.4× 193 1.9× 33 0.4× 42 0.7× 31 305
Ting‐Jung Wu Taiwan 11 94 0.6× 112 1.1× 165 1.6× 69 0.8× 82 1.4× 21 359
Zexin Zhu China 10 64 0.4× 85 0.8× 136 1.3× 67 0.8× 73 1.2× 19 304

Countries citing papers authored by Daniel Almquist

Since Specialization
Citations

This map shows the geographic impact of Daniel Almquist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Almquist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Almquist more than expected).

Fields of papers citing papers by Daniel Almquist

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Almquist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Almquist. The network helps show where Daniel Almquist may publish in the future.

Co-authorship network of co-authors of Daniel Almquist

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Almquist. A scholar is included among the top collaborators of Daniel Almquist based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Almquist. Daniel Almquist is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Almquist, Daniel, Blake Langlais, Konstantinos Leventakos, et al.. (2023). Chemoimmunotherapy in patients with extensive‐stage small cell lung cancer and a poor performance status. Cancer. 129(22). 3546–3553. 7 indexed citations
2.
Langlais, Blake, Konstantinos Leventakos, Nathan Y. Yu, et al.. (2023). Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3. Clinical Lung Cancer. 24(7). 591–597. 7 indexed citations
3.
Almquist, Daniel, et al.. (2023). Treatment landscape of advanced high-grade neuroendocrine neoplasms.. PubMed. 21(1). 16–26. 5 indexed citations
4.
Almquist, Daniel, Vinicius Ernani, & Mohamad Bassam Sonbol. (2021). Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: DIPNECH. Current Opinion in Pulmonary Medicine. 27(4). 255–261. 5 indexed citations
5.
Almquist, Daniel, Blake Langlais, Nathan Y. Yu, et al.. (2021). Chemoimmunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in patients with an Eastern Cooperative Group (ECOG) performance status (PS) of two or greater.. Journal of Clinical Oncology. 39(15_suppl). 8569–8569. 1 indexed citations
6.
Al‐Toubah, Taymeyah, Jonathan Strosberg, Þorvarður R. Hálfdánarson, et al.. (2020). Somatostatin Analogs Improve Respiratory Symptoms in Patients With Diffuse Idiopathic Neuroendocrine Cell Hyperplasia. CHEST Journal. 158(1). 401–405. 19 indexed citations
7.
DeLeon, Thomas, Daniel Almquist, Benjamin R. Kipp, et al.. (2020). Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. PLoS ONE. 15(3). e0230306–e0230306. 23 indexed citations
8.
Sonbol, Mohamad Bassam, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, et al.. (2020). Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma. JAMA Oncology. 6(12). e204930–e204930. 137 indexed citations
9.
Almquist, Daniel, Daniel H. Ahn, & Tanios Bekaii‐Saab. (2020). The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. BioDrugs. 34(3). 349–362. 35 indexed citations
10.
Almquist, Daniel, Mohamad Bassam Sonbol, Helen J. Ross, et al.. (2020). Clinical Characteristics of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia. CHEST Journal. 159(1). 432–434. 11 indexed citations
11.
Almquist, Daniel & Vinicius Ernani. (2020). The Road Less Traveled: A Guide to Metastatic ROS1-Rearranged Non–Small-Cell Lung Cancer. JCO Oncology Practice. 17(1). 7–14. 13 indexed citations
12.
Almquist, Daniel, Mohamad Bassam Sonbol, Heidi Kosiorek, et al.. (2019). DIPNECH: The Mayo experience.. Journal of Clinical Oncology. 37(15_suppl). e20029–e20029. 4 indexed citations
13.
Hilal, Talal, Lanyu Mi, Natalie Ertz-Archambault, et al.. (2019). Change in 21‐gene Recurrence Score result after exposure to neo‐adjuvant endocrine therapy in patients with operable breast cancer. The Breast Journal. 26(7). 1449–1451. 1 indexed citations
14.
Almquist, Daniel, Milind Javle, Kristen K. Ciombor, et al.. (2019). FGFR2 fusions and its effect of patient (pt) outcomes in intrahepatic cholangiocarcinoma (iCCA). Annals of Oncology. 30. v279–v279. 5 indexed citations
15.
Dhakal, Prajwal, et al.. (2019). Initial management of immune thrombocytopaenia in adults based on risk stratification. Postgraduate Medical Journal. 95(1128). 558–562. 2 indexed citations
16.
Almquist, Daniel, et al.. (2018). Preoperative Pulmonary Function Tests (PFTs) and Outcomes from Resected Early Stage Non-small Cell Lung Cancer (NSCLC). Anticancer Research. 38(5). 2903–2907. 14 indexed citations
17.
Almquist, Daniel, et al.. (2018). Sequential HER2-Targeted Therapy in Salivary Ductal Carcinoma With HER2/neu Overexpression and a Concomitant ERBB2 Mutation. JCO Precision Oncology. 2(2). 1–5. 2 indexed citations
18.
Almquist, Daniel, et al.. (2016). Multimodality Therapy for Limited-Stage Small-Cell Lung Cancer. Journal of Oncology Practice. 12(2). 111–117. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Burcin Özdirik Breakdown of academic impact, for papers by Mark Karwal Breakdown of academic impact, for papers by Denise N. Gansen Breakdown of academic impact, for papers by Zhong-Guo Zhou Breakdown of academic impact, for papers by Loretta D’Onofrio Breakdown of academic impact, for papers by Ryu Otao Breakdown of academic impact, for papers by Satoshi Moriya Breakdown of academic impact, for papers by Ting‐Jung Wu Breakdown of academic impact, for papers by Zexin Zhu
Rankless by CCL
2026